These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16405555)

  • 1. Tongue and skin hyperpigmentation during PEG-interferon-alpha/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C.
    Gurguta C; Kauer C; Bergholz U; Formann E; Steindl-Munda P; Ferenci P
    Am J Gastroenterol; 2006 Jan; 101(1):197-8. PubMed ID: 16405555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tongue hyperpigmentation resulting from peginterferon alfa-2b and ribavirin treatment in a patient with chronic hepatitis C.
    Ghosh S; Duseja A; Dhiman RK; Chawla YK
    Dig Dis Sci; 2012 Mar; 57(3):820-1. PubMed ID: 21948358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tongue hyperpigmentation during PEG-interferon-alfa/ribavirin therapy in a non-Caucasian patient with chronic hepatitis C: a case report and review of the literature.
    Mlika RB; Kerkeni N; Marrak H; Fenniche S; Mokhtar I; Debbiche A
    Int J Dermatol; 2013 May; 52(5):643-4. PubMed ID: 23046405
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
    Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
    J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection.
    Elgouhari HM; Zein CO; Hanouneh I; Feldstein AE; Zein NN
    Dig Dis Sci; 2009 Dec; 54(12):2699-705. PubMed ID: 19148751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lingual hyperpigmentation from pegylated interferon and ribavirin treatment of hepatitis C.
    Farshidi D; Chiu MW
    J Am Acad Dermatol; 2010 Jan; 62(1):164-165. PubMed ID: 20082904
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
    Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
    J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tongue hyperpigmentation resulting from peginterferon alpha-2a and ribavirin treatment in a Caucasian patient with chronic hepatitis C.
    Fernández A; Vázquez S; Rodríguez-González L
    J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1389-91. PubMed ID: 18355209
    [No Abstract]   [Full Text] [Related]  

  • 9. Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection.
    Willems M; Munte K; Vrolijk JM; Den Hollander JC; Böhm M; Kemmeren MH; De Man RA; Brouwer JT
    Br J Dermatol; 2003 Aug; 149(2):390-4. PubMed ID: 12932249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary hyperpigmentation during interferon alfa treatment for chronic hepatitis C virus infection.
    Tsilika K; Tran A; Trucchi R; Pop S; Anty R; Cardot-Leccia N; Lacour JP; Ortonne JP; Passeron T
    JAMA Dermatol; 2013 Jun; 149(6):675-7. PubMed ID: 23553009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
    Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
    World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
    Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1233-40. PubMed ID: 22098185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy.
    Yu ML; Dai CY; Lee LP; Hsieh MY; Hou NJ; Huang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Antivir Ther; 2006; 11(8):1015-9. PubMed ID: 17302371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.
    El Naghi S; Abdel-Ghaffar TY; El-Karaksy H; Abdel-Aty EF; El-Raziky MS; Allam AA; Helmy H; El-Araby HA; Behairy BE; El-Guindi MA; El-Sebaie H; Abdel-Ghaffar AY; Ehsan NA; El-Hennawy AM; Sira MM
    World J Gastroenterol; 2014 Apr; 20(16):4681-91. PubMed ID: 24782620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
    Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C.
    Minami T; Kishikawa T; Sato M; Tateishi R; Yoshida H; Koike K
    J Gastroenterol; 2013 Feb; 48(2):254-68. PubMed ID: 22790350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin.
    Conti F; Vukotic R; Lorenzini S; Riili A; Cursaro C; Scuteri A; Loggi E; Galli S; Furlini G; Bernardi M; Andreone P
    Ann Hepatol; 2014; 13(2):196-203. PubMed ID: 24552861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.
    Jacobson IM; Gonzalez SA; Ahmed F; Lebovics E; Min AD; Bodenheimer HC; Esposito SP; Brown RS; Bräu N; Klion FM; Tobias H; Bini EJ; Brodsky N; Cerulli MA; Aytaman A; Gardner PW; Geders JM; Spivack JE; Rahmin MG; Berman DH; Ehrlich J; Russo MW; Chait M; Rovner D; Edlin BR
    Am J Gastroenterol; 2005 Nov; 100(11):2453-62. PubMed ID: 16279900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.